Granted Patent
B2
US 12,398,186 · App. 18/047,751 · Granted Aug 26, 2025
Multi-chain chimeric polypeptides and uses thereof
Assignee:
ImmunityBio, Inc.
C07K14/5434C07K14/54C07K14/5418C07K14/71C07K14/7155C07K14/745C07K16/283C07K2317/622C07K2319/02C07K2319/03C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are multi-chain chimeric polypeptides that include: (a) a first chimeric polypeptide including a first target-binding domain, a soluble tissue factor domain, and a first domain of a pair of affinity domains; and (b) a second chimeric polypeptide including a second domain of a pair of affinity domains and a second target-binding domain, where the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains. Also provided here are methods of using these multi-chain chimeric polypeptides and nucleic acids encoding these multi-chain chimeric polypeptides.
Claims (53)
1. A nucleic acid encoding a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain;
(ii) a soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO: 1; and
(iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO: 14; and
(b) a second chimeric polypeptide comprising:
(i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO: 28; and
(ii) a second target-binding domain,
wherein:
the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains; and
the first target-binding domain and the second target-binding domain each comprise a soluble TGF-β receptor II (TGF-βRII) and each comprise a sequence that is at least 90% identical to SEQ ID NO: 85.
2. The nucleic acid of claim 1 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other in the first chimeric polypeptide.
3. The nucleic acid of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain in the first chimeric polypeptide.
4. The nucleic acid of claim 1 , wherein the soluble tissue factor domain and the first domain of the pair of affinity domains directly abut each other in the first chimeric polypeptide.
5. The nucleic acid of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the pair of affinity domains in the first chimeric polypeptide.
6. The nucleic acid of claim 1 , wherein the second domain of the pair of affinity domains and the second target-binding domain directly abut each other in the second chimeric polypeptide.
7. The nucleic acid of claim 1 , wherein the second chimeric polypeptide further comprises a linker sequence between the second domain of the pair of affinity domains and the second target-binding domain in the second chimeric polypeptide.
8. The nucleic acid of claim 1 , wherein the first chimeric polypeptide further comprises one or more additional target-binding domain(s).
9. The nucleic acid of claim 1 , wherein the second chimeric polypeptide further comprises one or more additional target-binding domain(s).
10. The nucleic acid of claim 1 , wherein the soluble human tissue factor domain comprises a sequence that is at least 95% identical to SEQ ID NO: 1.
11. The nucleic acid of claim 1 , wherein the first target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 85.
12. The nucleic acid of claim 1 , wherein the first target-binding domain comprises a sequence that is at least 99% identical to SEQ ID NO: 85.
13. The nucleic acid of claim 1 , wherein the first target-binding domain comprises a sequence of SEQ ID NO: 85.
14. The nucleic acid of claim 1 , wherein:
the first chimeric polypeptide comprises a sequence of SEQ ID NO: 133; and
the second chimeric polypeptide comprises a sequence of SEQ ID NO: 177.
15. The nucleic acid of claim 14 , wherein:
the first chimeric polypeptide comprises a sequence of SEQ ID NO: 135; and
the second chimeric polypeptide comprises a sequence of SEQ ID NO: 92.
16. The nucleic acid of claim 1 , wherein the second target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 85.
17. The nucleic acid of claim 1 , wherein the second target-binding domain comprises a sequence that is at least 99% identical to SEQ ID NO: 85.
18. The nucleic acid of claim 1 , wherein the second target-binding domain comprises a sequence of SEQ ID NO: 85.
19. The nucleic acid of claim 1 , wherein:
the first and second target-binding domain each comprise a sequence that is at least 95% identical to SEQ ID NO: 85;
the soluble tissue factor domain is at least 95% identical to SEQ ID NO: 1;
the first domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 14; and
the second domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 28.
20. The nucleic acid of claim 1 , wherein the first domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 14, and the second domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 28.
21. The nucleic acid of claim 1 , wherein:
the first and second target-binding domain each comprise a sequence that is at least 99% identical to SEQ ID NO: 85;
the soluble tissue factor domain is at least 99% identical to SEQ ID NO: 1;
the first domain of the pair of affinity domains comprises a sequence that is at least 99% identical to SEQ ID NO: 14; and
the second domain of the pair of affinity domains comprises a sequence that is at least 99% identical to SEQ ID NO: 28.
22. The nucleic acid of claim 1 , wherein the first domain of the pair of affinity domains comprises a sequence that is at least 99% identical to SEQ ID NO: 14, and the second domain of the pair of affinity domains comprises a sequence that is at least 99% identical to SEQ ID NO: 28.
23. The nucleic acid of claim 1 , wherein the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 133, and the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 177.
24. The nucleic acid of claim 1 , wherein the first chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 133, and the second chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 177.
25. The nucleic acid of claim 1 , wherein the first chimeric polypeptide comprises a sequence that is at least 99% identical to SEQ ID NO: 133, and the second chimeric polypeptide comprises a sequence that is at least 99% identical to SEQ ID NO: 177.
26. A vector comprising the nucleic acid of claim 1 .
27. A first vector and a second vector that together comprise the nucleic acid of claim 1 , wherein the first vector comprises a nucleic acid encoding the first chimeric polypeptide, and wherein the second vector comprises a nucleic acid encoding the second chimeric polypeptide.
28. A cell comprising the nucleic acid of claim 1 .
29. A method of producing a multi-chain chimeric polypeptide, the method comprising:
culturing the cell of claim 28 in a culture medium under conditions sufficient to result in the production of the multi-chain chimeric polypeptide; and
recovering the multi-chain chimeric polypeptide from the cell and/or the culture medium.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 17, 2024
From: HCW BIOLOGICS INC.
To: IMMUNITYBIO, INC.
Reel/Frame 068014/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 13, 2023
From: WONG, HING
To: HCW BIOLOGICS, INC.
Reel/Frame 064240/0637 →
Continuity (12)
Provisional Application
62881088
· Jul 31, 2019
Provisional Application
62817230
· Mar 12, 2019
Provisional Application
62817241
· Mar 12, 2019
Provisional Application
62816683
· Mar 11, 2019
Provisional Application
62749506
· Oct 23, 2018
Provisional Application
62749007
· Oct 22, 2018
Provisional Application
62746832
· Oct 17, 2018
Provisional Application
62724969
· Aug 30, 2018
Provisional Application
62725043
· Aug 30, 2018
Provisional Application
62725010
· Aug 30, 2018
References Cited (400)
US 5595756A
· Bally et al.
· 1997
[cited by applicant]
US 6117980A
· Gonzalez et al.
· 2000
[cited by applicant]
US 7452537B2
· Bauer et al.
· 2008
[cited by applicant]
US 7482436B2
· Sugimura et al.
· 2009
[cited by applicant]
US 7488802B2
· Collins et al.
· 2009
[cited by applicant]
US 7521051B2
· Collins et al.
· 2009
[cited by applicant]
US 7612181B2
· Wu et al.
· 2009
[cited by applicant]
US 7691380B2
· Thorpe et al.
· 2010
[cited by applicant]
US 7723482B2
· Soulillou et al.
· 2010
[cited by applicant]
US 7968094B2
· Jiao et al.
· 2011
[cited by applicant]
US 8007795B2
· Jiao et al.
· 2011
[cited by applicant]
US 8133485B2
· Levi-Schaffer et al.
· 2012
[cited by applicant]
US 8217149B2
· Irving et al.
· 2012
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8475792B2
· Dall'Acqua
· 2013
[cited by examiner]
US 8552156B2
· Takayanagi et al.
· 2013
[cited by applicant]
US 8586714B2
· Ghayur et al.
· 2013
[cited by applicant]
US 8716450B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8722855B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8735546B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8741604B2
· Campbell et al.
· 2014
[cited by applicant]
US 8753640B2
· Wu et al.
· 2014
[cited by applicant]
US 8759494B2
· Bachmann et al.
· 2014
[cited by applicant]
US 8822645B2
· Ghayur et al.
· 2014
[cited by applicant]
US 9035026B2
· Hoffmann et al.
· 2015
[cited by applicant]
US 9067997B2
· Romagne et al.
· 2015
[cited by applicant]
US 9085623B2
· Rother et al.
· 2015
[cited by applicant]
US 9090684B2
· Borras et al.
· 2015
[cited by applicant]
US 9226962B2
· Le Gall et al.
· 2016
[cited by applicant]
US 9238084B2
· Liu et al.
· 2016
[cited by applicant]
US 9273136B2
· Rader et al.
· 2016
[cited by applicant]
US 9371395B2
· Takahashi et al.
· 2016
[cited by applicant]
US 9441034B2
· Sivakumar et al.
· 2016
[cited by applicant]
US 9505843B2
· Kim et al.
· 2016
[cited by applicant]
US 9617345B2
· Berne et al.
· 2017
[cited by applicant]
US 9701758B2
· Cooper et al.
· 2017
[cited by applicant]
US 20010044427A1
· Mazel et al.
· 2001
[cited by applicant]
US 20060159655A1
· Collins et al.
· 2006
[cited by applicant]
US 20070160579A1
· Schmitz et al.
· 2007
[cited by applicant]
US 20120171197A1
· Eriksson et al.
· 2012
[cited by applicant]
US 20120264920A1
· Wang et al.
· 2012
[cited by applicant]
US 20140242077A1
· Choi
· 2014
[cited by applicant]
US 20150259429A1
· Benaroch et al.
· 2015
[cited by applicant]
US 20160175397A1
· Umana et al.
· 2016
[cited by applicant]
US 20170198042A1
· Williams et al.
· 2017
[cited by applicant]
US 20180200366A1
· Wong
· 2018
[cited by applicant]
US 20200123607A1
· Serrano Marugan et al.
· 2020
[cited by applicant]
US 20210061897A1
· Ledbetter et al.
· 2021
[cited by applicant]
US 20230372399A1
· Wong
· 2023
[cited by applicant]
US 20230398151A1
· Wong
· 2023
[cited by applicant]
CN 1844150
· 2006
[cited by applicant]
CN 101653603
· 2010
[cited by applicant]
CN 101965364
· 2011
[cited by applicant]
CN 102153653
· 2011
[cited by applicant]
CN 106255703
· 2016
[cited by applicant]
CN 109513003
· 2019
[cited by applicant]
EP 1245676
· 2002
[cited by applicant]
EP 1719528
· 2006
[cited by applicant]
EP 2537933
· 2012
[cited by applicant]
EP 3029069
· 2016
[cited by applicant]
EP 3348276
· 2018
[cited by applicant]
JP 2005124568
· 2005
[cited by applicant]
JP 2008536487
· 2008
[cited by applicant]
JP 2009512433
· 2009
[cited by applicant]
JP 4361133
· 2009
[cited by applicant]
KR 20160127688
· 2016
[cited by applicant]
KR 101778439
· 2017
[cited by applicant]
WO WO1995015341
· 1995
[cited by applicant]
WO WO1996001653
· 1996
[cited by applicant]
WO WO2001083755
· 2001
[cited by applicant]
WO WO2002083152
· 2002
[cited by applicant]
WO WO2003037911
· 2003
[cited by applicant]
WO WO2003104425
· 2003
[cited by applicant]
WO WO2004076488
· 2004
[cited by applicant]
WO WO2006096828
· 2006
[cited by applicant]
WO WO2006097743
· 2006
[cited by applicant]
WO WO2006119897
· 2006
[cited by applicant]
WO WO2008096158
· 2008
[cited by applicant]
WO WO2011127324
· 2011
[cited by applicant]
WO WO2012040323
· 2012
[cited by applicant]
WO WO2012120125
· 2012
[cited by applicant]
WO WO2012170470
· 2012
[cited by applicant]
WO WO2012175222
· 2012
[cited by applicant]
WO WO2012175692
· 2012
[cited by applicant]
WO WO2013068946
· 2013
[cited by applicant]
WO WO2014007513
· 2014
[cited by applicant]
WO WO2014026054
· 2014
[cited by applicant]
WO WO2014095808
· 2014
[cited by applicant]
WO WO2014130635
· 2014
[cited by applicant]
WO WO2014159531
· 2014
[cited by applicant]
WO WO2015089881
· 2015
[cited by applicant]
WO WO2016106221
· 2016
[cited by applicant]
WO WO2016154585
· 2016
[cited by applicant]
WO WO2016166348
· 2016
[cited by applicant]
WO WO2017053748
· 2017
[cited by applicant]
WO WO2017083612
· 2017
[cited by applicant]
WO WO2017149538
· 2017
[cited by applicant]
WO WO2017189526
· 2017
[cited by applicant]
WO WO2018067825
· 2018
[cited by applicant]
WO WO2018075989
· 2018
[cited by applicant]
WO WO2018129007
· 2018
[cited by applicant]
WO WO2018158350
· 2018
[cited by applicant]
WO WO2018183169
· 2018
[cited by applicant]
WO WO2018165208
· 2018
[cited by applicant]
WO WO2019046313
· 2019
[cited by applicant]
WO WO2020047333
· 2020
[cited by applicant]
WO WO2020047462
· 2020
[cited by applicant]
WO WO2020047473
· 2020
[cited by applicant]
WO WO2021163369
· 2021
[cited by applicant]
Chan et al., “Molecular mechanisms of natural killer cell activation in response to cellular stress,” Cell Death & Differentiation, Jan. 2014, 21(1):5-14.
[cited by applicant]
Chang et al., “The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity,” Clinical cancer research, Sep. 15, 2007, 13(18…
[cited by applicant]
Hui et al., “Butyrate inhibit collagen-induced arthritis via Treg/IL-10/Th17 axis,” International immunopharmacology, Mar. 1, 2019, 68: Abstract 1 page.
[cited by applicant]
Li et al., “Lipid metabolism fuels cancer's spread,” Cell metabolism, Feb. 7, 2017, 25(2):228-230.
[cited by applicant]
Wilchek et al., “Essentials of biorecognition: The (strept) avidin-biotin system as a model for protein-protein and protein-ligand interaction,” Immunology letters, Feb. 28, 2006, 103(1): Abstract 2 pages.
[cited by applicant]
Zhang et al., “Depletion of NK cells improves cognitive function in the Alzheimer disease mouse model, ” The Journal of Immunology, Jul. 15, 2020, 205(2): 10pages.
[cited by applicant]
Chen et al., “A novel idea for establishing Parkinson's disease mouse model by intranasal administration of paraquat” Neurological Research, 43(4):267-277, 2021.
[cited by applicant]
Igarashi et al., “VEGF-C and TGF-β reciprocally regulate mesenchymal stem cell commitment to differentiation into lymphatic endothelial or osteoblastic phenotypes,” International journal of molecular medicine, 37(4):100…
[cited by applicant]
Infante-Duarte et al., “New developments in understanding and treating neuroinflammation” Journal of Molecular Medicine, 86:975-985, Sep. 2008.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2023/065745, mailed on Jun. 26, 2023, 14 pages.
[cited by applicant]
Janeway et al., “The interaction of the antibody molecule with specific antigen” In Immunobiology: The Immune System in Health and Disease, 5th edition, 5 pages, 2001.
[cited by applicant]
Matsuura et al., “Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion” Journal of neuroscience methods, 73(1):45-48, 1997.
[cited by applicant]
Reddy et al., “Linkers in the structural biology of protein-protein interactions” Protein science, 22(2):153-167, 2013.
[cited by applicant]
Ross et al., “Signaling and function of interleukin-2 in T lymphocytes” Annual review of immunology, 36:411-433, 2018.
[cited by applicant]
Van Bockstaele et al., “The development of nanobodies for therapeutic applications” Current opinion in investigational drugs, 10(11):1212-1224, 2009.
[cited by applicant]
[No Author Listed], “CN Br-activated Sepharose 4 Fast Flow,” 1999, Affinity Chromatography, 4 pages.
[cited by applicant]
Brämer et al., “Membrane adsorber for the fast purification of a monoclonal antibody using protein a chromatography,” Membranes, Nov. 27, 2019, 9(12):159, 15 pages.
[cited by applicant]
Chabannon et al., “Manufacturing natural killer cells as medicinal products,” Frontiers in Immunology, Nov. 15, 2016, 7(504): 1-9.
[cited by applicant]
Guha et al., “Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles,” Proceedings of the National Academy of Sciences, Jan. 1986, 83(2):299-302.
[cited by applicant]
Hélie et al., “Application of the Protein Maker as a platform purification system for therapeutic antibody research and development,” Computational and Structural Biotechnology Journal, Jan. 1, 2016, 14:238-244.
[cited by applicant]
info.gbiosciences.com [Online], “G-Biosciences, The Basics of Affinity Purification/Affinity Chromatography,” Jul. 31, 2018, retrieved on Apr. 18, 2023, retrieved from URL<https://info.gbiosciences.com/blog/the-basics-o…
[cited by applicant]
Klingemann et al., “Natural killer cells for immunotherapy-advantages of the NK-92 cell line over blood NK cells, ” Frontiers in Immunology, Mar. 14, 2016, 7(91): 1-7.
[cited by applicant]
Kozlowska et al., “Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice,” Cancer Immunology, Immunotherapy, Jul. 2016, 65:835-845.
[cited by applicant]
Putnam et al., “Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation,” American Journal of Transplantation, Nov. 1, 2013, 13(11):3010-3020.
[cited by applicant]
ThermoFisher.com [Online], “Covalent Immobilization of Affinity Ligands,” 2018, retrieved on Apr. 18, 2023, retrieved from <URLhttps://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learnin…
[cited by applicant]
Uppendahl et al., “Natural killer cell-based immunotherapy in gynecologic malignancy: a review,” Frontiers in Immunology, Jan. 5, 2018, 8(1825): 1-15.
[cited by applicant]
Urh et al., “Affinity chromatography: general methods,” Methods in Enzymology, Jan. 1, 2009, 463: 23 pages.
[cited by applicant]
Veluchamy et al., “The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments,” Frontiers in Immunology, May 31, 2017, 8(631): 1-20.
[cited by applicant]
Zhou, “Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity,” Cytokine & Growth Factor Reviews, Jun. 30, 2022, 67: 80-88.
[cited by applicant]
Fernando et al., “Targeting tumor endothelial marker 8 in the tumor vasculature of colorectal carcinomas in mice,” Cancer Research, Jun. 15, 2009, 69(12):5126-5132.
[cited by applicant]
Mortier et al., “Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ: hyperagonist IL-15. IL-15Rα fusion proteins,” Journal of Biological Chemistry, Jan.…
[cited by applicant]
Wong et al., “Interleukin-15: Interleukin-15 receptor a scaffold for creation of multivalent targeted immune molecules,” Protein Engineering, Design & Selection, Apr. 1, 2011, 24(4):373-383.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/035598, mailed Dec. 6, 2022, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/035285, mailed Dec. 15, 2022, 7 pages.
[cited by applicant]
Shen et al., “Engineering peptide linkers for scFv immunosensors,” Anal Chem., Mar. 2008, 80(6):1910-1917.
[cited by applicant]
Bartscht et al., “Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of…
[cited by applicant]
Bird et al., “TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence,” Science translational medicine, Aug. 15, 2018, 10(454):eaan 1230, 15 pages.
[cited by applicant]
Cai et al., “Quercetin inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in human retinal pigment epithelial cells via the Smad pathway,” Drug design, development and therapy, Dec. 6, 2018…
[cited by applicant]
Abbott et al., “Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene,” Immunogentics, Sep. 1994, 40(5):331-338.
[cited by applicant]
Abdul-Aziz et al., “Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment,” Blood, Jan. 31, 2019, 133(5):446-456.
[cited by applicant]
Aertgeerts et al., “Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation, ” Protein Science, Feb. 2004, 13(2):4…
[cited by applicant]
Ait-Oufella el al., “Natural regulatory T cells control the development of atherosclerosis in mice,” Nature Medicine, Feb. 5, 2006, 12:178-180.
[cited by applicant]
Akbari, et al., “Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR),” Protein Expr. Purif., 2016, 127:8-15.
[cited by applicant]
Ali et al., “Regulatory T cells in skin,” Immunology, Jul. 12, 2017, 152(3):372-381.
[cited by applicant]
Angevin et al., “First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers,” British Journal of Cancer, Mar. 14, 2017, 116(9):1126-1134.
[cited by applicant]
Bachelet et al., “Mast Cell Costimulation by CD226/CD112 (DNAM-1/Nectin-2) A Novel Interface in the Allergic Process,” Journal of Biological Chemistry, Sep. 15, 2006, 281(37):27190-6.
[cited by applicant]
Baker et al., “Chronic treatment with the beta(2)-adrenoceptor agonist prodrug BRL-47672 impairs rat skeletal muscle function by inducing a comprehensive shift to a faster muscle phenotype,” J Pharmacol Exp Ther., Oct. …
[cited by applicant]
Baker et al., “Effects of conjugated linoleic acid (CLA) on tissue composition parameters in a murine cachexia model,” The FASEB Journal, Mar. 2006, 20(4), 2 pages (Abstract Only).
[cited by applicant]
Baker, et al., “Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders,” Nature, 2011, 479(7372): 232-236.
[cited by applicant]
Bennett et al., “Erratum: Killing the old: cell senescence in atherosclerosis,” Nature Reviews Cardiology, Jan. 12, 2017, 14(3):132.
[cited by applicant]
Bennett et al., “Killing the old: cell senescence in atherosclerosis,” Nature Reviews Cardiology, Dec. 12, 2016, 14(1):8-9, 2 pages.
[cited by applicant]
Bentebibel et al., “A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Raf Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors,” Cancer Discovery, Jun. 2019, 9(6):711-721.
[cited by applicant]
Berry et al., “Cancer Anorexia and Cachexia: Screening in an Ambulatory Infusion Service and Nutrition Consultation, ” Clin J Oncol Nurs., 2018, 22(1):63-68.
[cited by applicant]
Bhat et al., “Astrocyte Senescence as a Component of Alzheimer's Disease, ” PLoS One, Sep. 12, 2012, 7(9):e45069, 10 pages.
[cited by applicant]
Biran et al., “Senescent cells communicate via intercellular protein transfer,” Genes & Development, Apr. 8, 2015, 29(8):791-802, 13 pages.
[cited by applicant]
Borea et al., “Pharmacology of Adenosine Receptors: The State of the Art,” Physiological Reviews 98(3):1591-1625, 2018.
[cited by applicant]
Borgerding et al., “B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression,” Experimental Hematology, Mar. 1, 2010, 38(3):213-21.
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 2000, 10:398-400.
[cited by applicant]
Bourgeois et al., “Regulation of cellular senescence via the FOXO4-p53 axis, ” FEBS Lett., 2018, 592(12): 2083-2097.
[cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 1990, 247:1306-1310.
[cited by applicant]
Boyman et al., “IL-7/Anti-IL-7 mAb Complexes Restore T Cell Development and Induce Homeostatic T Cell Expansion without Lymphopenia, ” The Journal of Immunology, Jun. 1, 2008, 180:7265-7275.
[cited by applicant]
Boyman et al., “Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes,” Science, Mar. 31, 2006, 311(5769):1924-1927.
[cited by applicant]
Brennan et al., “Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface,” PNAS, 2017, 114(31):8348-8353.
[cited by applicant]
Brighton et al., “Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium,” Elife, Dec. 11, 2017, 6:e31274, 23 pages.
[cited by applicant]
Brooks et al., “Combined inhibition of PD1 and CD96 checkpoints improves survival in a resectable murine model of pancreatic cancer,” European Journal of Cancer, Jul. 1, 2016, 61:S189, 1 page.
[cited by applicant]
Broxmeyer et al., “Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26,” Stem Cells and Development, Mar. 4, 2016, 25(8):575-585.
[cited by applicant]
Brunstein et al., “Infusion of Ex Vivo Expanded T Regulatory Cells in Adults Transplanted with Umbilical Cord Blood: Safety Profile and Detection Kinetics,” Blood, Jan. 20, 2011, 117(3):1061-1070.
[cited by applicant]
Brunstein et al., “Umbilical cord blood-derived T regulatory cells to prevent GVHD:kinetics, toxicity profile, and clinical effect,” Blood, Feb. 25, 2016, 127(8):1044-1051.
[cited by applicant]
Buhling et al., “Functional role of CD26 on human B lymphocytes,” Immunology Letters, Feb. 1995, 45(1-2):47-51.
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) GrowthFactor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single …
[cited by applicant]
Bussian et al., “Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline,” Nature, Sep. 19, 2018, 562(7728):578-582, 21 pages.
[cited by applicant]
Cai et al., “Chibby suppresses aerobic glycolysis and proliferation of nasopharyngeal carcinoma via the Wnt/β-catenin-Lin28/let7-PDK1 cascade,” Journal of Experimental & Clinical Cancer Research, Dec. 1, 2018, 37(1):104.
[cited by applicant]
Cao et al., “Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy,” Biotechnology Letters, Jul. 1, 2015, 37(7):1347-54.
[cited by applicant]
Cao, “Self-regulation and cross-regulation of pattern-recognition receptor signaling in health and disease,” Nature Reviews Immunology, Dec. 29, 2015, 16(1):35-50.
[cited by applicant]
Carr et al., “NK Cell-Mediated Lysis of Autologous HCMV-Infected Skin Fibroblasts Is Highly Variable among NK Cell Clones and Polyclonal NK Cell Lines,” Clinical Immunology, Nov. 2002, 105(2):126-140.
[cited by applicant]
Catania et al., “The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer,” Cell Adhesi…
[cited by applicant]
Cavinato et al., “Molecular mechanisms of UVB-induced senescence of dermal fibroblasts and its relevance for photoaging of the human skin,” Experimental Gerontology. Aug. 2017, 94:78-82.
[cited by applicant]
Chalan et al., “Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis,” PLoS ONE, 2015, 10(7):e0132436.
[cited by applicant]
Chambers et al., “Can blocking inflammation enhance immunity during aging?,” Journal of Allergy and Clinical Immunology, May 2020, 145(5):1323-1331.
[cited by applicant]
Chance et al., “A simple and rapid assay of oxidative phosphorylation,” Nature, Jun. 1955, 175(4469):1120-1121.
[cited by applicant]
Chandrudu et al., “Chemical methods for peptide and protein production,” Molecules, 2013, 18(4):4373-4388.
[cited by applicant]
Chang et al., “Association Between Sarcopenia and Cognitive Impairment: A Systematic Review and Meta-Analysis,” J Am Med Dir Assoc., Dec. 1, 2016, 17(12):1164e7-1164e15, 9 pages.
[cited by applicant]
Chattopadyhay et al., “Structural Basis of Inducible Costimulator Ligand Costimulatory Function: Determination of the Cell Surface Oligomeric State and Functional Mapping of the Receptor Binding Site of the Protein1,” J…
[cited by applicant]
Chen et al., “Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts,” Diabetes Care, Feb. 2009, 32(2):329-334.
[cited by applicant]
Chen et al., “Sterile inflammation: sensing and reacting to damage,” Nature Reviews Immunology, Nov. 19, 2010, 10(12):826-837.
[cited by applicant]
Chichili et al., “Linkers in the structural biology of protein-protein interactions,” Protein Science, Feb. 2013, 22(2):153-67.
[cited by applicant]
Childs et al., “Senescent cells: an emerging target for diseases of ageing,” Nature Reviews Drug Discovery, Jul. 21, 2017, 16(10):718-735, 18 pages.
[cited by applicant]
Childs et al., “Senescent intimal foam cells are deleterious at all stages of atherosclerosis,” Science, Oct. 28, 2016, 354(6311):472-477.
[cited by applicant]
Chinta, et al., “Cellular senescence is induced by the environmental neurotoxin paraquat and bontributes to neuropathology linked to Parkinson's Disease,” Cell Rep., 2018, 22(4): 930-940.
[cited by applicant]
Chong et al., “CD36 initiates the secretory phenotype during the establishment of cellular senescence, ” EMBO Rep., May 18, 2018, 19(6):e45274, 13 pages.
[cited by applicant]
Ciaglia, et al., “Recognition by natural killer cells of N6-isopentenyladensoine-treated human glioma cell lines,” Int. J. Cancer, 2018 142(1): 176-190.
[cited by applicant]
Cichocki et al., “GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity,” Cancer Research, Oct. 15, 2017, 77(20):5664-75.
[cited by applicant]
Cifaldi et al., “Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective,” Trends Molecular Medicine, Dec. 2017, 23(12):1156-1175, 20 pages.
[cited by applicant]
Cipriani et al., “Hippocampal Radial Glial Subtypes and Their Neurogenic Potential in Human Fetuses and Healthy and Alzheimer's Disease Adults,” Cerebral Cortex, May 2, 2018, 28(7):2458-2478, 21 pages.
[cited by applicant]
Clayton et al.,“Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8 T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression,” J Viral.…
[cited by applicant]
Collado et al., “Senescence in tumours: evidence from mice and humans,” Nature Reviews Cancer, Jan. 2010, 10(1):51-57.
[cited by applicant]
Conarello et al., “Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance,” Proc. Natl. Acad. Sci. U.S.A., May 27, 2003, 100(11):6825-6830.
[cited by applicant]
Conlon et al., “Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors,” Cancer Res. 79(13 Suppl.):CT082, Jul. 1, 2019, 2 page…
[cited by applicant]
Coppe et al., “Tumor Suppressor and Aging Biomarker p16INK4a Induces Cellular Senescence without the Associated Inflammatory Secretory Phenotype,” Journal of Biological Chemistry, Oct. 21, 2011, 286(42): 36396-36403.
[cited by applicant]
Cosgrove et al., “Usher protein functions in hair cells and photoreceptors,” Int J Biochem Cell Biol., Jan. 2014, 46:80-89.
[cited by applicant]
Cosman et al., “ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor,” Immunity, Feb. 1, 2001, 14(2):123-33.
[cited by applicant]
Costa et al., “Targeting the epidermal growth factor receptor can counteract the inhibition of natural killer cell function exerted by colorectal tumor-associated fibroblasts,” Frontiers in Immunology, May 29, 2018, 9:1…
[cited by applicant]
Crews et al., “Molecular mechanisms of neurodegeneration in Alzheimer's disease,” Human Molecular Genetics, Apr. 22, 2010, 19(R1):R12-R20, 9 pages.
[cited by applicant]
Cromie et al., “Nanobodies and their use in GPCR drug discovery,” Current Topics in Medicinal Chemistry, Dec. 1, 2015, 15(24):2543-57.
[cited by applicant]
Czaja et al., “A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs,” Genes and Immunity, Jan. 2014, 15(1), 15 pages.
[cited by applicant]
Da Silva et al., “Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy,” Nature Immunology, Jun. 15, 2015, 16(8):850-858, 11 pages.
[cited by applicant]
Dall'Era et al., “Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus,” Arthritis Rheumatology, Mar. 2019, 71(3):431-440.
[cited by applicant]
De Crescenzo et al., “Engineering TGF-β Traps: Artificially Dimerized Receptor Ectodomains as High-affinity Blockers of TGF-β Action,” Transforming Growth Factor-β in Cancer Therapy, vol. II, 2008, Humana Press, 671-84.
[cited by applicant]
De Genst et al., “Antibody repertoire development in camelids,” Developmental & Comparative Immunology, Jan. 1, 2006, 30(1-2):187-98.
[cited by applicant]
De Meyer et al., “Nanobody-based products as research and diagnostic tools,” Trends in Biotechnology, May 1, 2014, 32(5):263-70.
[cited by applicant]
De Stefano et al., “Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, Jan. 2016, 87(1):93-99.
[cited by applicant]
Deacon, “Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes,” Frontiers in Endocrinology, Feb. 2019, 10:80, 14 pages.
[cited by applicant]
Deaglio et al., “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” Journal of Experimental Medicine, May 14, 2007, 204(6):1257-1265.
[cited by applicant]
Demaria et al., “An Essential Role for Senescent Cellsin Optimal Wound Healingthrough Secretion of PDGF-AA,” Developmental Cell, Dec. 22, 2014, 31(6):722-733.
[cited by applicant]
Deyev et al., “Design of multivalent complexes using the barnase· barstar module,” Nature Biotechnology, Dec. 2003, 21(12):1486-92.
[cited by applicant]
Di Ianni et al., “Tregs prevent GVHD and promote immune reconstitution inHLA-haploidentical transplantation, ” Blood, Apr. 7, 2011, 117(14):3921-3928.
[cited by applicant]
Dietel et al., “Decreased Nos. of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells,” Atherosclerosis, Sep. 2013, 230:92-99.
[cited by applicant]
DiGiammarino et al., “Design and generation of DVD-Ig™ molecules for dual-specific targeting,” Therapeutic Proteins: Methods and Protocols, Methods in Molecular Biology, 2012, Humana Press, Totowa, NJ., 899:145-516.
[cited by applicant]
Dikov et al., “New fluorescent method for the histochemical detection of tripeptidyl peptidase I using glycyl-1-prolyl-1-met-2-anthraquinonyl hydrazide as substrate,” Cellular and Molecular Biology, Jan. 1, 2004, 50 Onl…
[cited by applicant]
Dimri et al., “A biomarker that identifies senescent human cells in culture and in aging skin in vivo,” Proceedings of the National Academy of Sciences, Sep. 29, 1995, 92(20):9363-9367.
[cited by applicant]
Dinarello, “Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process,” The American Journal of Clinical Nutrition, Feb. 1, 2006, 83(2):447S-455S.
[cited by applicant]
Docagne et al., “A soluble transforming growth factor-β (TGF-β) type I receptor mimics TGF-β responses,” Journal of Biological Chemistry, Dec. 7, 2001, 276(49):46243-50.
[cited by applicant]
Dong et al., “Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response,” Journal of Immunology, Feb. 15, 1996, 156(4):1349-1355.
[cited by applicant]
Dong et al., “Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation,” Journal of Immunology, Dec. 15, 1997, 159(12):6070-6076.
[cited by applicant]
Dong et al., “Loss of methylation at theIFNGpromoter and CNS-1 is associated with the development of functional IFN-γ memory in human CD4+T lymphocytes,” European Journal of Immunology, 2013, 43(3), 793-804.
[cited by applicant]
Dou et al., “Cytoplasmic chromatin triggers inflammation in senescence and cancer,” Nature, Oct. 4, 2017, 550(7676):402-406, 21 pages.
[cited by applicant]
Drees, et al., “Soluble production of a biologically active single-chain antibody against murine PD-L1 in
[cited by applicant]
Dubois et al., “Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action,” The Journal of Immunology, Feb. 15, 2008, 180:2099-2106.
[cited by applicant]
Edwardraja et al., “Redesigning of anti-c-met single chain Fv antibody for the cytoplasmic folding and its structural analysis,” Biotechnology and Bioengineering, Jun. 15, 2010, 106(3):367-75.
[cited by applicant]
Eisenhut et al., “Ion Channels in Inflammation,” Pflugers Archive, Jan. 29, 2011, 461(4):401-421.
[cited by applicant]
Elgueta et al., “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” Immunological Reviews, 2009, 229(1):152-172 doi.org/10.1111/j.1600-065X.2009.00782.x.
[cited by applicant]
Elpek et al., “Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes,” Proceedings of the National Academy of Science, Dec. 14, 2010, 1…
[cited by applicant]
Engel et al., “The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism,” Proc. Natl. Acad. Sci. U.S.A., Apr. 29, 2003, 100(9):5063-5068.
[cited by applicant]
Epardaud et al., “Interleukin-15/Interleukin-15RA Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells,” Cancer Research 68: Apr. 15, 2008, 2972-2983.
[cited by applicant]
Esensten et al., “Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier,” The Journal of Allergy and Clinical Immunology, Dec. 1, 2018, 142(6):1710-1718.
[cited by applicant]
Farr, et al., “Targeting cellular senescence prevents age-related bone loss in mice,” Nat. Med., 2017, 23(9): 1072-1079.
[cited by applicant]
Fehniger et al., “A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia,” Biology of Blood and Marrow Transplantation, Aug. 2018, 24(8):1581-1589.
[cited by applicant]
Feng et al., “The yin and yang functions of extracellular ATP and adenosine in tumor immunity,” Cancer Cell International, Apr. 7, 2020, 20:110, 11 pages.
[cited by applicant]
Ferreira et al., “Next-generation regulatory T cell therapy,” Nature Reviews Drug Discovery, Sep. 20, 2019, 18(10):749-769, 21 pages.
[cited by applicant]
Ferrucci et al., “The origins of age-related proinflammatory state,” Blood, Mar. 15, 2005, 105(6):2294-2299.
[cited by applicant]
Finkelman et al., “Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes,” The Journal of Immunology, Aug. 1, 1993…
[cited by applicant]
Finkelstein et al., “Obesity and Severe Obesity Forecasts Through 2030,” American Journal of Preventative Medicine, Jun. 2012, 42(6):563-570.
[cited by applicant]
Ford et al., “TREM and TREM-like receptors in inflammation and disease,” Current Opinion in Immunology, Feb. 21, 2009, 21(1):38-46.
[cited by applicant]
Franceschi et al., “Inflamm-aging. An evolutionary perspective on immunosenescence,” Annals of the New York Academy of Sciences, Jun. 2000, 908:244-254.
[cited by applicant]
Frutoso et al., “Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles,” Journal of Immunology, May 30, 2018, 201: 493-506.
[cited by applicant]
Ganesh et al., “TGF-β Inhibition and Immunotherapy: Checkmate,” Immunity, Apr. 17, 2018, 48(4):626-628.
[cited by applicant]
Garber, “Bispecific antibodies rise again,” Nat. Rev. Drug Discov., 2014, 13:799-801.
[cited by applicant]
Gaulton et al., “Characterization of a monoclonal rat anti-mouse interleukin 2 (IL-2) receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor,” Clinical Immunology and Immunopatholo…
[cited by applicant]
Gejima et al., “Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling,” Human Antibodies, Jan. 1, 2002, 11(4):121-9.
[cited by applicant]
Geng et al., “A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides,” Immunol. Res. 62(3):377-385, 2015.
[cited by applicant]
Georgilis et al., “PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells,” Cancer Cell, Jul. 9, 2018, 34(1):85-102.
[cited by applicant]
Ghosh et al., “The Senescence-Associated Secretory Phenotype: Critical Effector in SkinCancer and Aging,” Journal of Investigative Dermatology, Nov. 2016, 136(11):2133-2139.
[cited by applicant]
Gibbs et al., “Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis,” Biochemistry, Nov. 1, 1994, 33(47):14003-10.
[cited by applicant]
Gong et al., “DAMP-sensing receptors in sterile inflammation and inflammatory diseases,” Nature Reviews Immunology, Sep. 26, 2019, 20(2):95-112.
[cited by applicant]
Gorrell et al., “Expression of the rat CD26 Antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes,” Cellular Immunology, Apr. 15, 1991, 134(1):205-215.
[cited by applicant]
Greenspan et al., “Defining epitopes: Its not as easy as it seems,” Nature Biotechnology, 1999, 17:936-937.
[cited by applicant]
Grupp et al., “Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia,” The New England Journal of Medicine, Apr. 18, 2013, 368(16):1509-1518.
[cited by applicant]
Gu et al., “Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions,” Cellular and Molecular Immunology, Jul. 4, 2016, 14(6):521-528.
[cited by applicant]
Guo et al., “Immunobiology of the IL-15-IL-15R complex as an antitumor and antiviral agent,” 2017, Cytokine & Growth Factor Reviews, 38:10-21.
[cited by applicant]
Gutschmidt et al., “A quantitative histochemical study of dipeptidyl peptidase IV (DPP IV),” Histochemistry, 1981, 73(2):285-304.
[cited by applicant]
Haile et al., “Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression,” J. Immunol., 2013, 191(5):2829-2836.
[cited by applicant]
Hayflick et al., “The serial cultivation of human diploid cell strains, ” Experimental Cell Research, Dec. 1961, 25:585-621.
[cited by applicant]
He et al., “Senescence in Health and Disease,” Cell, Jun. 1, 2017, 169(6):1000-1011.
[cited by applicant]
Hebbar et al., “Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis,” Clinical & Experimental Immunology, May 2004, 136(2):388-92.
[cited by applicant]
Helfrich et al., “A rapid and versatile method for harnessing scFv antibody fragments with varous biological effector functions,” Journal of Immunological methods, 2000, 237(1-2):131-145 DOI:1O.1O16/S0022-1759(99)OO220-…
[cited by applicant]
Helman et al., “Effects of ageing and senescence on pancreatic β-cell function,” Diabetes Obes Metab., Sep. 2016, 18(Suppl. 1):58-62.
[cited by applicant]
Heneka et al., “Inflammasome signaling in brain function and neurodegenerative disease,” Nature Reviews Neuroscience, Sep. 11, 2018, 19(10):610-621.
[cited by applicant]
Heneka et al., “NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice,” Nature, Jan. 31, 2013, 493(7434):674-678, 8 pages.
[cited by applicant]
Heng et al., “G Protein-Coupled Receptors Revisited: Therapeutic Applications Inspired by Synthetic Biology,” Annual Review of Pharmacology and Toxicology, Jan. 2014, 54:227-249.
[cited by applicant]
Heng et al., Sophea, et al. “Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signalling.” Placenta, 2017 57: 320 (1 page).
[cited by applicant]
Highfill et al., “Overcoming Challenges in Process Development of Cellular Therapies,” Current Hematologic Malignancy Reports, Jul. 6, 2019, 14(4):269-277, 9 pages.
[cited by applicant]
Hoare et al., “The Power Behind the Throne: Senescence and the Hallmarks of Cancer,” Annual Review of Cancer Biology, 2018, 2:175-194.
[cited by applicant]
Hoffmann et al., “Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T Cells,” Blood, Aug. 2004, 104(3):895-903.
[cited by applicant]
Hollande et al., “Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth,” Nature Immunology, Feb. 18, 2019, 20(3):257-264.
[cited by applicant]
Hombach et al., “Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3,” Scandinavian Journal of Immunology, Nov. 1998, 48(5):497-501.
[cited by applicant]
Hu et al., “Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy,” Scientific Reports, 2018, 8:7675, 11 pages.
[cited by applicant]
Huang et al., “Substrate recognition by tissue factor-factor VIIa Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X,” Journal of Biological Chemi…
[cited by applicant]
Huang et al., “Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD) 3-tTF” The Scientific World Journal, 2013(637086): 1-11, 2013.
[cited by applicant]
Hudak et al., “Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion,” Nature Chemical Biology, Jan. 2014, 10(1), 20 pages.
[cited by applicant]
Hudson et al., “Targeting RAGE Signaling in Inflammatory Disease,” Annual Review of Medicine, Jan. 2018, 69:349-364, 16 pages.
[cited by applicant]
Huell et al., “Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients,” Acta Neuropathologica, Nov. 1995, 89(6):544-551.
[cited by applicant]
Hughes, et al., “Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions,” Hum. Gene Ther., 2005, 16:457-72.
[cited by applicant]
Hynes et al., “In vitro analysis of cell metabolism using a long-decay pH-sensitive lanthanide probe and extracellular acidification assay,” Analytical biochemistry, Jul. 1, 2009, 390(1):21-28.
[cited by applicant]
Iannello et al., “p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells,” Journal of Experimental Medicine, Sep. 23, 2013, 210(10):2057-69.
[cited by applicant]
Iihoshi et al., “Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells,” Toxicology Letters, Aug. 5, 2017, 277:109-114, 22 pag…
[cited by applicant]
Inzucchi et al., “New Drugs for the Treatment of Diabetes, Part II: Incretin-Based Therapy and Beyond, ” Circulation, Jan. 29, 2008, 117(4):574-584, 21 pages.
[cited by applicant]
Jain et al., “Mitochondrial Reactive Oxygen Species Regulate Transforming Growth Factor-β Signaling,” Journal of Biological Chemistry, Jan. 11, 2013, 288(2):770-777.
[cited by applicant]
Jakob et al., “Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule,” Mabs, May 1, 2013, Taylor & Francis, 5(3):358-63.
[cited by applicant]
Janeway, “Approaching the Asymptote? Evolution and Revolution in Immunology,” Cold Spring Harbor Symposia on Quantitative Biology, 1989, 54 Pt 1:1-13.
[cited by applicant]
Jeannin et al., “Soluble CD86 Is a Costimulatory Moleculefor Human T Lymphocytes,” Immunity, 2000, 13(3):303-312.
[cited by applicant]
Jeon et al., “Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment,” Nat Med., Jun. 2017, 23(6):775-781.
[cited by applicant]
Jin et al., “Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis,” Journal of the American Heart Association, Jun. 11, 2019, 8(12):e012219, 12 pages.
[cited by applicant]
Justice et al., “Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study,” EBioMedicine, Feb. 2019, 40:554-563.
[cited by applicant]
Kain et al., “The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides,” Immunity, Oct. 16, 2014, 41(4):543-54.
[cited by applicant]
Karin et al., “Senescent cell turnover slows with age providing an explanation for the Gompertz law,” Nature Communications, 10:5495, 9 pages, Dec. 2, 2019.
[cited by applicant]
Karkera et al., “The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study,” The Prostate, Feb. 14, 2011, 71(13):1455-1465.
[cited by applicant]
Katsuumi et al., “Vascular Senescence in Cardiovascular and Metabolic Diseases,” Frontiers in Cardiovascular Medicine, 5:18, 13 pages, Mar. 5, 2018.
[cited by applicant]
Kellner et al., “Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30,” Oncoimmunology, Jan. 2, 2016, 5(1):e1058459,…
[cited by applicant]
Kijanka et al., “Nanobody-based cancer therapy of solid tumors, ” Nanomedicine, Jan. 2015, 10(1):161-74.
[cited by applicant]
Kim et al., “Experimental malaria infection triggers early expansion of natural killer cells,” Infection and Immunity, Dec. 1, 2008, 76(12):5873-82.
[cited by applicant]
Kim et al., “Identification of senescent cell surface targetable protein DPP4,” Genes & Development, 2017, 31(15):1529-1534.
[cited by applicant]
Kim et al., “Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components,” Hepatol Int., Jun. 2013, 7(2):586-591.
[cited by applicant]
Kim et al., “SCAMP4 enhances the senescent cell secretome,” Genes & Development, 2018, 32(13-14):909-914.
[cited by applicant]
Kirchhofer et al., “The tissue factor region that interacts with substrates factor IX and factor X,” Biochemistry, Jun. 27, 2000, 39(25):7380-7.
[cited by applicant]
Kirkland et al., “Cellular Senescence: A Translational Perspective,” EBioMedicine, Jul. 2017, 21:21-28.
[cited by applicant]
Klein et al., “Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokine…
[cited by applicant]
Klein et al., “Design and characterization of structured protein linkers with differing flexibilities,” Protein Engineering, Design & Selection, 2014, 27(10):325-30.
[cited by applicant]
Klemann et al., “Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system,” Clinical and Experimental Immunology, Feb. 25, 2016, 185(1):1-21.
[cited by applicant]
Klingenberg et al., “Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis,” The Journal of Clinical Investigation, Feb. 15, 2013, 123:1323-1334.
[cited by applicant]
Kondo et al., “Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells,” Human Immunology, 2007, 68(7):563-571.
[cited by applicant]
Kovaleva et al., “Shark variable new antigen receptor biologics-a novel technology platform for therapeutic drug development,” Expert Opinion on Biological Therapy, Oct. 1, 2014, 14(10):1527-39.
[cited by applicant]
Krah et al., “Single-domain antibodies for biomedical applications,” Immunopharmacology and Immunotoxicology, Jan. 2, 2016, 38(1):21-8.
[cited by applicant]
Kritsilis et al., “Ageing, Cellular Senescence and Neurodegenerative Disease,” International Journal of Molecular Sciences, Sep. 27, 2018, 19(10):2937, 37 pages.
[cited by applicant]
Krizhanovsky et al., “Senescence of activated stellate cells limits liver fibrosis,” Cell, Aug. 22, 2008, 134(4):657-67.
[cited by applicant]
Kumagai et al., “Monitoring of glutamate-induced excitotoxicity by mitochondrial oxygen consumption,” Synapse, Jan. 2019, 73(1):e22067, 24 Pages.
[cited by applicant]
Kuyinu et al., “Animal models of osteoarthritis: classification, update, and measurement of outcomes,” J Orthop Surg Res., Feb. 2, 2016, 11:19, 27 pages.
[cited by applicant]
Lambeir et al., “Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV,” Critical Reviews in Clinical Laboratory Sciences, Sep. 29, 2003,…
[cited by applicant]
Lamkanfi et al., “Mechanisms and Functions of Inflammasomes,” Cell, May 22, 2014, 157(5):1013-1022.
[cited by applicant]
Lansigan et al., “DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Reco…
[cited by applicant]
Latz et al., “Activation and regulation of the inflammasomes,” Nature Reviews Immunology, May 24, 2013, 13(6):397-411.
[cited by applicant]
Latz et al., “NLRP3 inflammasome activation in inflammaging,” Seminars in Immunology, Dec. 2018, 40:61-73, 13 pages.
[cited by applicant]
Lau et al., “RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement,” The Journal of Experimental Medicine, Oct. 31, 2005, 202(9):1171-1177.
[cited by applicant]
Lazar et al., “Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol., 1988, 8:1247-1252.
[cited by applicant]
Li et al., “A Novel I L2-based Irrmunotherapeutic Protein Prevents the Development of Atherosclerosis in ApoE-/mice and LDLR-/- mice,” Journal of Immunology, May 1, 2020, 204(1):Supplement (Abstract Only), 2 pages.
[cited by applicant]
Li et al., “Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma,” Cytotherapy, Jan. 2018, 20(1): 134-148, 15 pages.
[cited by applicant]
Li et al., “The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer,” Journal of Experimental Medicine, Apr. 5, 2018, 215(5):1287-1299.
[cited by applicant]
Li et al., “Transforming Growth Factor-β Regulation of Immune Responses,” Annu. Rev. Immunol., 2006, 24:99-146.
[cited by applicant]
Liton et al., “Cellular senescence in the glaucomatous outflow pathway,” Experimental Gerontology, August-Sep. 2005, 40(8-9):745-748.
[cited by applicant]
Liu et al., “A Novel Fusion of ALT-803 (IL-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses,” Journal of Biological Chemistry, 2016, 291(46):23869-23881.
[cited by applicant]
Liu et al., “Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models,” Cytokine, Jul. 2018, 107: 105-112, 8 pages.
[cited by applicant]
Loster et al., “The Cysteine-Rich Region of Dipeptidyl Peptidase IV (CD 26) Is the Collagen Binding Site,” Biochemical and Biophysical Research Communications, Dec. 5, 1995, 217(1):341-348.
[cited by applicant]
Lu et al., “Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26,” Nature, Jul. 7, 2013, 500(7461):227-231.
[cited by applicant]
Lujambio et al., “Non-Cell-Autonomous Tumor Suppression by p53,” Cell, Apr. 11, 2013, 153(2):449-460.
[cited by applicant]
Maeda et al., “Original Ligand for LTβR Is LIGHT: Insight into Evolution of the LT/LTβR System,” J Immunol., 2018, 201(1):202-214.
[cited by applicant]
Maganto-García et al., “Dynamic Changes in Regulatory T Cells Are Linked to Levels of Diet-Induced Hypercholesterolemia,” Circulation, Jun. 20, 2011, 124:185-195.
[cited by applicant]
Mandelboim et al., “Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells,” Nature, Feb. 2001, 409(6823):1055.
[cited by applicant]
Marguet et al., “Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26,” Proc. Natl. Acad. Sci. U.S.A., Jun. 6, 2000, 97(12):6874-6879.
[cited by applicant]
Martelli et al., “HLA-haploidentical transplantation with regulatory and conventionalT-cell adoptive immunotherapy prevents acute leukemia relapse,” Blood, Jul. 24, 2014, 124(4):638-644.
[cited by applicant]
Masoumi et al., “The role of hypoxia as the driving force for non-erythroid production of globin chains in preeclamptic placentas,” Placenta. 2017;57:320.
[cited by applicant]
McCarron et al., “TGF-β prevents T follicular helper cell accumulation and B cell autoreactivity,” J Clin Invest., 2014, 124(10):4375-4386.
[cited by applicant]
McHugh et al., “Senescence and aging: Causes, consequences, and therapeutic avenues,” Journal of Cellular Biology, Nov. 7, 2017, 217(1):65-77.
[cited by applicant]
Mehta et al., “Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015,” Expert Opinion on Investigational Drugs, May 2017, 26(6):735-739.
[cited by applicant]
Melk et al., “Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney,” Kidney Int., Feb. 2004, 65(2):510-520.
[cited by applicant]
Melk et al., “Senescence of renal cells: molecular basis and clinical implications,” Nephrology Dialysis Transplantation, Dec. 2003, 18(12):2474-2478.
[cited by applicant]
Menshawy et al., “CD58; leucocyte function adhesion-3 (LFA-3) could be used as a differentiating marker between immune and non-immune thyroid disorders,” Comparative Clinical Pathology, 2018, 27(3), 721-727, doi.org/10.…
[cited by applicant]
Mentlein et al., “Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides,” Regulatory Peptides, Nov. 30, 1999, 85(1):9-24.
[cited by applicant]
Miah et al., “KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules,” The Journal of Immunology, Mar. 1, 2008, 180(5):2922-32.
[cited by applicant]
Michelet et al., “Metabolic reprogramming of natural killer cells in obesity limits antitumor responses,” Nature Immunology, Nov. 12, 2018, 19(12):1330-1340.
[cited by applicant]
Mikayama et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,” Proc. Natl. Acad. Sci. USA, Nov. 1, 1993, 90(21):10056-10060.
[cited by applicant]
Milanovic et al., “Senescence-associated reprogramming promotes cancer stemness,” Nature, Dec. 20, 2017, 553(7686):96-100.
[cited by applicant]
Milanovic et al., “The Senescence-Stemness Alliance—A Cancer-Hijacked Regeneration Principle,” Trends in Cellular Biology, Dec. 2018, 28(12): 1049-1061, 13 pages.
[cited by applicant]
Miller et al., “Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma,” J Neurosurg., 2010, 113(2):280-285.
[cited by applicant]
Miller et al., “Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer,” Blood, Apr. 15, 2005, 105(8):3051-3057.
[cited by applicant]
Minamino et al., “A crucial role for adipose tissue p53 in the regulation of insulin resistance,” Nature Medicine, Aug. 30, 2009, 15(9):1082-1087.
[cited by applicant]
Mitterberger et al., “Adipogenic Differentiation Is Impaired in Replicative Senescent Human Subcutaneous Adipose-Derived Stromal/Progenitor Cells,” The Journals of Gerontology: Series A, Biological Sciences and Medical …
[cited by applicant]